Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Indena S.p.A. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are both situated within 1 distinct art unit, which implies that the company's current patent efforts are focused on a specific niche within the biotech sector. This concentration in 1 distinct art unit can often lead to more predictable prosecution if the unit's general tendencies are well understood.
The company's active applications are being reviewed by 2 distinct examiners. RAO, SAVITHA M is the busiest examiner, currently managing 1 busiest examiner pending office action. This means the 2 pending office actions are split evenly between RAO, SAVITHA M and one other examiner. Practitioners should be prepared to navigate the individual nuances of 2 distinct examiners while addressing the overarching standards of the 1 distinct art unit.
Managing 2 pending office actions in the Biotechnology & Pharmaceuticals space requires careful attention to detail. Since both 2 distinct examiners are operating within the same 1 distinct art unit, there may be overlap in the prior art cited against the applications. The strategy for Indena S.p.A. should involve a coordinated effort to ensure that responses to RAO, SAVITHA M are consistent with the arguments presented to the other examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695504 | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES | KOSAR, ANDREW D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835362 | QUERCETIN-BASED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR AFFECTIONS | RAO, SAVITHA M | — |
| 18695504 | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835362 | QUERCETIN-BASED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR AFFECTIONS | RAO, SAVITHA M | — | §103DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18695504 | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES | KOSAR, ANDREW D | 1625 | §103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial